期刊
CELL
卷 181, 期 7, 页码 1612-+出版社
CELL PRESS
DOI: 10.1016/j.cell.2020.05.017
关键词
-
资金
- Parker Institute for Cancer Immunotherapy
- NIH [R01CA194511, R01CA223484, U01CA233100, U01CA244452, T32CA177555, K08AI139375]
- Conquer Cancer Foundation of the American Society of Clinical Oncology
- Bladder Cancer Advocacy Network Palm Beach New Discoveries Young Investigator Award
- Prostate Cancer Foundation Young Investigator Award
- Peter Michael Foundation
- Parker Institute of Cancer Immunotherapy
- Prostate Cancer Foundation
Responses to anti-PD-1 immunotherapy occur but are infrequent in bladder cancer. The specific T cells that mediate tumor rejection are unknown. T cells from human bladder tumors and non-malignant tissue were assessed with single-cell RNA and paired T cell receptor (TCR) sequencing of 30,604 T cells from 7 patients. We find that the states and repertoires of CD8(+) T cells are not distinct in tumors compared with non-malignant tissues. In contrast, single-cell analysis of CD4(+) T cells demonstrates several tumor-specific states, including multiple distinct states of regulatory T cells. Surprisingly, we also find multiple cytotoxic CD4(+) T cell states that are clonally expanded. These CD4(+) T cells can kill autologous tumors in an MHC class II-dependent fashion and are suppressed by regulatory T cells. Further, a gene signature of cytotoxic CD4(+) T cells in tumors predicts a clinical response in 244 metastatic bladder cancer patients treated with anti-PD-L1.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据